The UK National Screening Committee is consulting publicly until 4 November on whether an evaluation of screening for screening for severe combined immunodeficiency (SCID) should be undertaken in the NHS.
John is the Evidence Lead for the NHS Screening Programmes. He has worked for the UK National Screening Committee since 2003 and helped establish the evidence team in 2013.
The UK National Screening Committee (UK NSC) makes recommendations on all aspects of population screening. We make recommendations on more than 100 conditions, including recommendations to screen for more than 30.
Non-invasive prenatal testing (now more commonly called cfDNA, or cell-free DNA testing) is an exciting development and the UK NSC is now consulting on introducing it to the existing fetal anomaly screening programme (FASP). As new technology can only be introduced …
Related content and links
PHE Screening has paused its social media accounts while staff support the national response to Covid-19.
Any queries in relation to the provision of screening programmes during the COVID-19 response can be made to the NHSEI Incident Control Team.
The PHE Screening team
Public Health England (PHE) is the expert voice on screening, providing advice and guidance to the NHS. The national population screening programmes identify apparently healthy people who may be at increased risk of a disease or condition, enabling earlier treatment and informed decisions.
Find out more about PHE Screening and this blog.
Watch our 44 second video for an overview of how the blog works.